WO2008103327A3 - Mn/ca ix and bladder cancer - Google Patents

Mn/ca ix and bladder cancer Download PDF

Info

Publication number
WO2008103327A3
WO2008103327A3 PCT/US2008/002131 US2008002131W WO2008103327A3 WO 2008103327 A3 WO2008103327 A3 WO 2008103327A3 US 2008002131 W US2008002131 W US 2008002131W WO 2008103327 A3 WO2008103327 A3 WO 2008103327A3
Authority
WO
WIPO (PCT)
Prior art keywords
urinary tract
bladder cancer
patient
recurrence
monitor
Prior art date
Application number
PCT/US2008/002131
Other languages
French (fr)
Other versions
WO2008103327A2 (en
Inventor
Jan Zavada
Original Assignee
Bayer Pharmaceuticals Corp
Acad Of Science Czech Republic
Inst Of Molecular Genetics
Jan Zavada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Acad Of Science Czech Republic, Inst Of Molecular Genetics, Jan Zavada filed Critical Bayer Pharmaceuticals Corp
Publication of WO2008103327A2 publication Critical patent/WO2008103327A2/en
Publication of WO2008103327A3 publication Critical patent/WO2008103327A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is directed to methods to detect the presence or recurrence of urinary tract cancer, particularly bladder cancer, comprising the use of an immunoassay to detect soluble MN/CA IX (s-CA IX) in a patient urine sample. The disclosed methods are diagnostic/prognostic for urinary tract diseases, and useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to an anticancer therapy. The disclosed methods are further useful to select therapies for patients with urinary tract diseases. MN/CA IX is particularly identified as a sensitive and specific urinary marker for surveillance of urinary tract cancer recurrence, more particularly bladder cancer recurrence.
PCT/US2008/002131 2007-02-20 2008-02-19 Mn/ca ix and bladder cancer WO2008103327A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89073507P 2007-02-20 2007-02-20
US60/890,735 2007-02-20

Publications (2)

Publication Number Publication Date
WO2008103327A2 WO2008103327A2 (en) 2008-08-28
WO2008103327A3 true WO2008103327A3 (en) 2008-10-30

Family

ID=39710650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002131 WO2008103327A2 (en) 2007-02-20 2008-02-19 Mn/ca ix and bladder cancer

Country Status (1)

Country Link
WO (1) WO2008103327A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1487972T3 (en) 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] HUSSAIN S.A. ET AL.: "Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder", Database accession no. (15069539) *
ONCOL. REP., vol. 11, no. 5, May 2004 (2004-05-01), pages 1005 - 1010 *
SHERWOOD ET AL.: "Carbonic Anhydrase IX Expression and Outcome after Radiotherapy for Muscle-invasive Bladder Cancer", CLINICAL ONCOLOGY, vol. 19, 2007, pages 777 - 783, XP022323104 *
ZAVADA ET AL.: "Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of reneal carcinoma patients", BRITISH JOURNAL OF CANCER, vol. 89, 2003, pages 1067 - 1071 *

Also Published As

Publication number Publication date
WO2008103327A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2011028698A3 (en) Mri and optical assays for proteases
WO2008008483A3 (en) Dendrimer based compositions and methods of using the same
WO2006033766A3 (en) Dendrimer based compositions and methods of using the same
WO2005010486A3 (en) Biomarker panel for colorectal cancer
WO2007081767A3 (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
WO2007109571A3 (en) Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
WO2006091412A3 (en) Adamts-7 as a biomarker for cancers of epithelial origin
WO2006072947A8 (en) Endoscopic system for in-vivo procedures
HK1150884A1 (en) Seprase as a marker for cancer seprase
EP2301626A3 (en) Antibiotic for use in local infection
WO2006036220A3 (en) Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
WO2006024466A3 (en) Test device for the in vitro diagnosis of multi-analyte tests and the use thereof
WO2006073682A3 (en) Diagnostic test
EP2540840A3 (en) Genetic variants on CHR16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
BR112014013544A2 (en) Materials and methods for diagnosis, prognosis and evaluation of therapeutic / prophylactic treatment of prostate cancer
WO2008127388A3 (en) Use of quantum system identification and quantum control techniques for medical diagnostic and therapeutic purposes
WO2009057294A1 (en) Gene associated with liver cancer, and method for determination of the risk of acquiring liver cancer
WO2007088492A3 (en) Improved radiation therapy planning procedure
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007107774A3 (en) Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer
WO2008082673A3 (en) Companion diagnostic assays for cancer therapy
WO2007015926A3 (en) Multiparameter flow cytometric cytometric cytotoxicity systems, methods, compositions and kits for evaluating the susceptibility of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725733

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08725733

Country of ref document: EP

Kind code of ref document: A2